Associated tags: Agreement, Incyte, MET, Oncology, NSCLC, Medical imaging, Pharmaceutical industry, MSI-H, Metastasis, ESMO, European Society for Medical Oncology, Merkel-cell carcinoma, Lung cancer, Capmatinib, RECAP, Docetaxel, Abstract, Health, Melanoma, MCC, Endometrial cancer, Cohort, Standard of care
Oncology,
Health,
FDA,
Other Health,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Congress,
Standard of care,
Cohort,
Endometrial cancer,
MCC,
Melanoma,
Abstract,
NSCLC,
Docetaxel,
RECAP,
Capmatinib,
Lung cancer,
Merkel-cell carcinoma,
European Society for Medical Oncology,
ESMO,
Metastasis,
MSI-H,
Pharmaceutical industry,
Medical imaging,
Patient Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid.
Key Points:
- Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid.
- "We look forward to sharing data from our oncology portfolio with the scientific community at this year’s ESMO Congress,” said Steven Stein, M.D., Chief Medical Officer, Incyte.
- ET)
Updated Results from POD1UM-201: A Phase 2 Study of Retifanlimab in Patients with Advanced or Metastatic Merkel Cell Carcinoma (MCC) (Abstract #1146P.
- ET)
For full session details and data presentation listings, please see the ESMO Congress 2023 ( https://www.esmo.org/meeting-calendar/esmo-congress-2023/programme ) online program.
Retrieved on:
Wednesday, September 2, 2020
Oncology,
Health,
Genetics,
Clinical trials,
Pharmaceutical,
Biotechnology,
Life sciences,
Health,
Industries,
Breakthrough therapy,
Incyte,
Protein kinase inhibitor,
Antineoplastic drugs,
Orphan drugs,
Lung cancer,
Novartis,
Non-small-cell lung carcinoma,
Capmatinib,
Tabrecta,
Incyte The GEOMETRY mono-1 study results published in The New England Journal of Medicine further highlight the clinical benefit that Tabrecta can provide to patients with metastatic METex14 NSCLC, said Steven Stein, M.D., Chief Medical Officer, Incyte.
Key Points:
- The GEOMETRY mono-1 study results published in The New England Journal of Medicine further highlight the clinical benefit that Tabrecta can provide to patients with metastatic METex14 NSCLC, said Steven Stein, M.D., Chief Medical Officer, Incyte.
- Incyte is eligible for a total of over $500 million in milestones as well as royalties of between 12-14% on global net sales by Novartis.
- Tabrecta (capmatinib) is a kinase inhibitor that targets MET discovered by Incyte and licensed to Novartis in 2009.
- Under the terms of the Agreement, Incyte granted Novartis exclusive worldwide development and commercialization rights to capmatinib and certain back-up compounds in all indications.
Biotechnology,
Health,
Pharmaceutical,
Clinical trials,
Oncology,
Pharmaceutical companies,
Companies,
Life sciences,
Incyte,
Novartis,
Royalty payment,
Tabrecta,
Incyte Tabrecta is approved for first-line and previously treated patients, regardless of prior treatment type.
Key Points:
- Tabrecta is approved for first-line and previously treated patients, regardless of prior treatment type.
- Tabrecta is the third Incyte-discovered medicine to receive approval in Japan.
- Approval of Tabrecta in Japan triggers a $20 million milestone payment to Incyte, and Incyte is also eligible to receive 12-14% royalties on global net sales of Tabrecta by Novartis.
- This approval highlights the strength of the Incyte in-house discovery program, and our commitment to finding solutions for serious medical needs.
Oncology,
FDA,
Health,
Clinical trials,
Pharmaceutical,
Biotechnology,
Lung cancer,
Life sciences,
Pharmaceutical companies,
Companies,
Non-small-cell lung carcinoma,
Incyte,
Novartis,
Ceritinib,
Treatment of lung cancer,
GEOMETRY mono-1,
Tabrecta,
Incyte Tabrecta, the first and only treatment approved to specifically target NSCLC with this driver mutation, is approved for first-line and previously treated patients regardless of prior treatment type.
Key Points:
- Tabrecta, the first and only treatment approved to specifically target NSCLC with this driver mutation, is approved for first-line and previously treated patients regardless of prior treatment type.
- Novartis has exclusive worldwide development and commercialization rights to Tabrecta, and the FDA approval of Tabrecta triggers $70 million in milestone payments from Novartis to Incyte.
- We are pleased that the FDA has approved Tabrecta for patients with METex14 NSCLC, said Steven Stein, M.D., Chief Medical Officer, Incyte.
- Having a therapy that targets the recognized oncogenic driver will provide a much needed treatment option for patients with METex14 NSCLC who currently have limited treatment options.
